health and spending (a) Study The Comptroller General of the United States (in this section referred to as the Comptroller General ) shall, to the extent data are available, conduct a study on the use of prescription drugs to manage the weight of obese patients and the impact of coverage of such drugs on patient health and on health care spending. Such study shall examine the use and impact of these obesity drugs in the non-Medicare population and for Medicare beneficiaries who have such drugs covered through an MA–PD plan (as defined in section 1860D–1(a)(3)(C) of the Social Security Act ( 42 U.S.C. 1395w–101(a)(3)(C) )) as a supplemental health care benefit. The study shall include an analysis of the following: (1) The prevalence of obesity in the Medicare and non-Medicare population. (2) The utilization of obesity drugs. (3) The distribution of Body Mass Index by individuals taking obesity drugs, to the extent practicable. (4) What is known about the use of obesity drugs in conjunction with the receipt of other items or services, such as behavioral counseling, and how these compare to items and services received by obese individuals who do not take obesity drugs. (5) Physician considerations and attitudes related to prescribing obesity drugs. (6) The extent to which coverage policies cease or limit coverage for individuals who fail to receive clinical benefit. (7) What is known about the extent to which individuals who take obesity drugs adhere to the prescribed regimen. (8) What is known about the extent to which individuals who take obesity drugs maintain weight loss over time. (9) What is known about the subsequent impact such drugs have on medical services that are directly related to obesity, including with respect to subpopulations determined based on the extent of obesity. (10) What is known about the spending associated with the care of individuals who take obesity drugs, compared to the spending associated with the care of individuals who do not take such drugs. (b) Report Not later than 18 months